Table 4.
Attribute and level | Logit | |||
|
Estimate (SE) | P value | 95% CI | |
Collector | ||||
|
A technological company | −0.19 (0.02) | <.001 | −0.22 to −0.16 |
|
A research project | 0.08 (0.02) | <.001 | 0.05 to 0.11 |
|
Your health care provider (Refa) | 0.11 (N/Ab) | N/A | N/A |
New user | ||||
|
A technological company | −0.26 (0.02) | <.001 | −0.31 to −0.22 |
|
A pharmaceutical company | −0.03 (0.02) | .15 | −0.08 to 0.012 |
|
A research project | 0.12 (0.02) | <.001 | 0.08 to 0.16 |
|
A national authority (Ref) | 0.17 (N/A) | N/A | N/A |
Reason | ||||
|
Develop a new product or service | 0.15 (0.02) | <.001 | 0.11 to 0.20 |
|
Promoting, advertising, or marketing | −0.47 (0.02) | <.001 | −0.52 to −0.42 |
|
Investigate a policy initiative | 0.11 (0.02) | N/A | 0.07 to 0.15 |
|
Evaluate the quality (Ref) | 0.21 (N/A) | N/A | N/A |
Information | ||||
|
Not informed | −0.90 (0.02) | <.001 | −0.95 to −0.85 |
|
Informed | −0.08 (0.02) | .001 | −0.12 to −0.03 |
|
Informed and ability to opt out | 0.51 (0.02) | <.001 | 0.46 to 0.55 |
|
Informed and consent (Ref) | 0.47 (N/A) | N/A | N/A |
Reviewing | ||||
|
No specific review | −0.52 (0.02) | <.001 | −0.56 to −0.49 |
|
Review of sharing | 0.25 (0.02) | <.001 | 0.22 to 0.30 |
|
Review of sharing and use (Ref) | 0.27 (N/A) | N/A | N/A |
Intercept | 0.51 (0.01) | <.001 | 0.49 to 0.54 |
aReference category.
bN/A: not applicable.